Apr 27, 2026, 06:45 ETLilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and...
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026 Based on...